Update shared on05 Sep 2025
Maravai LifeSciences Holdings’ Future P/E has dropped sharply from 42.69x to 24.20x, reflecting improved earnings prospects or lowered growth expectations, while the fair value (analyst price target) remained unchanged at $4.12.
What's in the News
- Announced an organizational restructuring with a 25% workforce reduction and estimated $8–$9 million in related costs.
- Withdrew and suspended 2025 revenue guidance amid CEO and CFO transitions; new leadership conducting a comprehensive business review.
- Reported a $30.4 million goodwill impairment for the second quarter of 2025.
- Appointed Bernd Brust as CEO and Rajesh Asarpota as CFO, both with extensive life sciences and executive leadership backgrounds.
- Dropped from multiple Russell growth indices and added to multiple Russell value indices, reflecting a shift in index classification.
Valuation Changes
Summary of Valuation Changes for Maravai LifeSciences Holdings
- The Consensus Analyst Price Target remained effectively unchanged, at $4.12.
- The Future P/E for Maravai LifeSciences Holdings has significantly fallen from 42.69x to 24.20x.
- The Discount Rate for Maravai LifeSciences Holdings remained effectively unchanged, moving only marginally from 8.36% to 8.37%.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.